scholarly journals ANAESTHESIOLOGY AND INTENSIVE CARE Pulmonary function tests in the preoperative evaluation of lung cancer surgery candidates. A review of guidelines

2014 ◽  
Vol 3 ◽  
pp. 278-282
Author(s):  
Marzena Trzaska-Sobczak ◽  
Szymon Skoczyński ◽  
Władysław Pierzchała
Keyword(s):  
Lung Cancer ◽  
Intensive Care ◽  
Pulmonary Function ◽  
Pulmonary Function Tests ◽  
Preoperative Evaluation ◽  
Lung Cancer Surgery ◽  
Cancer Surgery ◽  
Function Tests

Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer

CHEST Journal ◽  
2009 ◽  
Vol 135 (6) ◽  
pp. 1588-1595 ◽  
Author(s):  
M. Patricia Rivera ◽  
Frank C. Detterbeck ◽  
Mark A. Socinski ◽  
Dominic T. Moore ◽  
Martin J. Edelman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Function ◽  
Small Cell Lung Cancer ◽  
Preoperative Chemotherapy ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Pulmonary Function Tests ◽  
Small Cell ◽  
Small Cell Lung ◽  
Function Tests

IMPACT OF PRE-OPERATIVE CHEMOTHERAPY ON PULMONARY FUNCTION TESTS IN RESECTABLE EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)

CHEST Journal ◽  
2008 ◽  
Vol 134 (4) ◽  
pp. 74P
Author(s):  
M.P. Rivera ◽  
Frank C. Detterbeck ◽  
Mark A. Socinski ◽  
Dominic T. Moore ◽  
Martin J. Edelman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Pulmonary Function Tests ◽  
Small Cell ◽  
Small Cell Lung ◽  
Function Tests

Pulmonary toxicity in patients receiving docetaxel chemotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e13532-e13532
Author(s):  
U. Kefeli ◽  
P. F. Yumuk ◽  
B. Ceyhan ◽  
F. Dane ◽  
B. Eroglu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Function ◽  
Cumulative Dose ◽  
Pulmonary Toxicity ◽  
Pulmonary Function Tests ◽  
Post Treatment ◽  
Function Tests ◽  
Significant Difference ◽  
Docetaxel Treatment ◽  
Docetaxel Chemotherapy

e13532 Background: Docetaxel is used widely as monotherapy or in combination for the treatment of various types of cancers. Although rarely observed, pulmonary toxicity can be seen with docetaxel. This side effect had been reported mostly in non-small cell lung cancer patients receiving docetaxel. We aimed to investigate the pulmonary toxicity in patients receiving docetaxel chemotherapy other than lung cancer. Methods: 34 patients were investigated prospectively to demonstrate the pulmonary toxicity of docetaxel. Pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) scans were applied to all patients before chemotherapy and 14 - 21 days after completion of treatment. We used a HRCT scoring system that was based on the previous studies. All HRCT images were reviewed by two different observers. Results: We have seen no pulmonary symptoms that may reflect pulmonary toxicity in 34 patients. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/sec) (p<0.05), FEV1/FVC (%) (p<0.05), FEF25–75 (L/sec) (p<0.01), FEF25–75 (%) (p<0,01), DLCO (mL/mmHg/min) (p<0.001), DLCO (%) (p<0.001), DLCO/VA (DLCO/L) (p<0.05), and DLCO/VA (%) (p<0.05). Also, there was a statistically significant difference between the pre- and post-treatment HRCT scores. The differences between pre- and post- treatment values of pulmonary function tests were not correlated with the number of docetaxel cycles and cumulative dose. There was a statistical relationship between number of docetaxel cycles (r =0.468, p<0.0001), docetaxel cumulative dose (r=0,596, p<0.0001) and HRCT scores after completion of docetaxel treatment. Conclusions: Although we have shown that docetaxel treatment causes a decline in PFTs and worsens HRCT scores, the symptoms of patients were not consistent with these differences. Therefore, it should be noted that the negative effects of docetaxel on PFTs and HRCT scores should be investigated by increasing the number of patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document